One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.
Authors: Russo Domenico , Martinelli Giovanni , Malagola Michele , Colombi Chiara , Rosti Giantonio , Amabile Marilina , Fogli Miriam , Turri Diamante , Mirto Salvatore , Gobbi Marco , Pierri Ivana , Vitolo Umberto , Pregno Patrizia , Morra Enrica , Pungolino Ester , Raimondo Francesco Di , Stagno Fabio , Foà Robin , Alimena Giuliana , Breccia Massimo , Nobile Francesco , Martino Bruno , Rambaldi Alessandro , Intermesoli Tamara , Saglio Giuseppe , Cambrin Giovanna Rege , Visani Giuseppe , Nicolini Giuseppina , Fabritiis Paolo de , Abruzzese Elisabetta , Fanin Renato , Tiribelli Mario , Galieni Piero , Bigazzi Catia , Specchia Giorgina , Liso Vincenzo , Angelucci Emanuele , Usala Emilio , Musolino Caterina , Russo Sabina , Gaidano Gianluca , Lunghi Monia , Lauria Francesco , Bocchia Monica , Rodeghiero Francesco , D'Emilio Anna , Bosi Alberto , Santini Valeria , Quarta Giovanni , Girasoli Mariella , Fioritoni Giuseppe , Lorenzo Roberto Di , Testoni Nicoletta , Vivo Antonio De , Soverini Simona , Iacobucci Ilaria , Baccarani Michele , Baccarani Michele 
Published: October 2019

Abstract 3412

The phase II explorative study of intermittent Imatinib (IM) treatment (InterIM) in elderly patients with Ph + chronic myeloid Leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) after at least 2-years standard IM therapy (any dose between 300 and 800 mg/day) was started in April 2008 and closed for the enrollment in August 2009, since more than 78 patients required by statistics were included into the study. The main objective of the study was to investigate if after 12 months (trial time) the CCgR achieved with standard (daily administration) IM therapy could be maintained with InterIM. For this purpose, the CgR status was assessed by Interphase Fluorescence In Situ Hybridization (I-FISH) on peripheral blood (≥ 200 cells counted) every 3 months. When I-FISH (% Ph + nuclei) increased more then 1%, chromosome banding analysis (CBA) on bone marrow was performed to confirm the loss of CCgR and to check for additional cytogenetic abnormalities (ACA). At the present time, out of the 95 patients who were enrolled, 82 patients were evaluable and out of them 77 (94%), 73 (89%), 71 (87%) and 70 (85%) completed 3, 6, 9 and 12 months of the treatment program, respectively. Therefore, the great majority of patients completed the study core and at the end of 2010 all the patients are expected to complete the trial time (12 mo). During the first 12 months of InterIM, 1% to 11% of the evaluable patients at 3, 6, 9 and 12 months showed an I-FISH >1% Ph+ nuclei (Figure 1).

Figure 1 Distribution of patients according to I-FISH Figure 1. Distribution of patients according to I-FISH

Totally, eleven (13%) out of 82 patients treated with InterIM showed an I-FISH >1% and they were checked by CBA on bone marrow (Figure 2). Out of them only 3 cases, that means 4% of the 82 evaluable patients, lost the CCgR and resumed standard IM therapy (daily administration), but none completed 3 months of therapy. All the patients lost the MMR and increased several folds the BCR-ABL transcript levels. Two pts had a low risk Sokal and one a high risk; age was 66, 69, 77 years; time from diagnosis was 29, 91 and 100 months; duration of IM therapy was 29, 83 and 84 months; the IM dose was 400mg in all cases.

Figure 2 Cytogenetic and molecular response in 11 cases who showed I-FISH >1% + nuclei and who were checked by CBA on bone marrow. Black boxes shows the 3 cases who lost the CCgR Figure 2. Cytogenetic and molecular response in 11 cases who showed I-FISH >1% + nuclei and who were checked by CBA on bone marrow. Black boxes shows the 3 cases who lost the CCgR

As concern as molecular response, 99% of the patients had a major molecular response (MMR=<0.001-0.1 BCR-ABL/ABLISX 100) at the baseline. The proportion of the patients who maintained the MMR after 3, 6, 9 and 12 months of InterIM was 95%, 92%, 91%, 84%, respectively. Interestingly, we found a weak but significant correlation between the % of BCR-ABL + nuclei and the BCR-ABL transcript levels in the patients who completed the trial time (12 mo) (r=0.27; p=0.001).

In conclusion, the results of the InterIM study core (12 months), clearly show that Intermittent Imatinib (IM) treatment (InterIM) is sufficient to maintain the complete cytogenetic response (CCgR) previously achieved with standard IM therapy in elderly (≥ 65 years) Ph+ CML patients. The risk to loose the CCgR has been very low (4%), while the benefit either in terms of reduction of IM dose and of costs of therapy or in terms of compliance (data not shown) was very high.

Acknowledgments:

This work was supported in part by CML-Leukemia Net and Progetto Regione Lombardia.

Disclosures:

No relevant conflicts of interest to declare.